Chosen Diagnostics Inc.

Chosen Diagnostics Inc. is a minority-owned, woman-owned small business registered with the U.S. federal government since August 2017. The company specializes in developing innovative diagnostic solutions for neonatal healthcare, particularly focusing on necrotizing enterocolitis (NEC), a potentially fatal gastrointestinal condition affecting premature infants. Chosen Diagnostics Inc. has received multiple federal grant awards to support its research and development efforts in creating early and accurate diagnostic tests for NEC, which could significantly improve medical interventions, reduce disease progression, and lower healthcare costs associated with this condition.

The company has been awarded several grants from the National Science Foundation (NSF) and the National Institute of Child Health and Human Development (NICHD) to further its work. These grants include a recent $999,749 Cooperative Agreement from the NSF's Technology, Innovation, and Partnerships program to develop reagents and reference standards for quantifying host biomolecules related to gut health in infants. Chosen Diagnostics Inc. is also working on a project funded by NICHD to develop a clinically-usable test for early diagnosis of gastrointestinal diseases in infants, with a focus on their proprietary biomarker, NECDetect. This biomarker provides a direct readout of an individual's ability to modulate gut homeostasis. The company's research aims to address the unique technical, logistic, and regulatory challenges associated with developing diagnostic tools for the neonatal population, with the ultimate goal of creating predictive disease segmentation models for infants using their NECDetect prototype and establishing reference values for the neonatal population.